GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Recordati SpA (OTCPK:RCDTF) » Definitions » Cyclically Adjusted PS Ratio

Recordati SpA (Recordati SpA) Cyclically Adjusted PS Ratio : 7.09 (As of May. 18, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Recordati SpA Cyclically Adjusted PS Ratio?

As of today (2024-05-18), Recordati SpA's current share price is $51.60. Recordati SpA's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $7.28. Recordati SpA's Cyclically Adjusted PS Ratio for today is 7.09.

The historical rank and industry rank for Recordati SpA's Cyclically Adjusted PS Ratio or its related term are showing as below:

RCDTF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 5.17   Med: 7.22   Max: 10.01
Current: 6.57

During the past years, Recordati SpA's highest Cyclically Adjusted PS Ratio was 10.01. The lowest was 5.17. And the median was 7.22.

RCDTF's Cyclically Adjusted PS Ratio is ranked worse than
87.52% of 745 companies
in the Drug Manufacturers industry
Industry Median: 2.17 vs RCDTF: 6.57

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Recordati SpA's adjusted revenue per share data for the three months ended in Dec. 2023 was $2.743. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $7.28 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Recordati SpA Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Recordati SpA's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recordati SpA Cyclically Adjusted PS Ratio Chart

Recordati SpA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.23 8.25 9.31 5.36 6.31

Recordati SpA Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.31 5.83 5.84 6.31 -

Competitive Comparison of Recordati SpA's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Recordati SpA's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Recordati SpA's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Recordati SpA's Cyclically Adjusted PS Ratio falls into.



Recordati SpA Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Recordati SpA's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=51.60/7.28
=7.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recordati SpA's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Recordati SpA's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.743/119.7000*119.7000
=2.743

Current CPI (Dec. 2023) = 119.7000.

Recordati SpA Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 1.701 99.907 2.038
201406 1.593 100.093 1.905
201409 1.475 99.814 1.769
201412 1.448 99.721 1.738
201503 1.424 99.814 1.708
201506 1.418 100.279 1.693
201509 1.314 100.000 1.573
201512 1.375 99.814 1.649
201603 1.609 99.600 1.934
201606 1.536 99.900 1.840
201609 1.473 100.100 1.761
201612 1.468 100.300 1.752
201703 1.747 101.000 2.070
201706 1.660 101.100 1.965
201709 1.783 101.200 2.109
201712 1.836 101.200 2.172
201803 2.161 101.800 2.541
201806 1.841 102.400 2.152
201809 1.769 102.600 2.064
201812 1.847 102.300 2.161
201903 2.067 102.800 2.407
201906 1.947 103.100 2.260
201909 1.883 102.900 2.190
201912 2.028 102.800 2.361
202003 2.269 102.900 2.639
202006 1.782 102.900 2.073
202009 1.880 102.300 2.200
202012 2.066 102.600 2.410
202103 2.222 103.700 2.565
202106 2.192 104.200 2.518
202109 2.168 104.900 2.474
202112 2.294 106.600 2.576
202203 2.206 110.400 2.392
202206 2.394 112.500 2.547
202209 2.299 114.200 2.410
202212 2.411 119.000 2.425
202303 2.824 118.800 2.845
202306 2.552 119.700 2.552
202309 2.613 120.300 2.600
202312 2.743 119.700 2.743

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Recordati SpA  (OTCPK:RCDTF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Recordati SpA Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Recordati SpA's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Recordati SpA (Recordati SpA) Business Description

Traded in Other Exchanges
Address
Via Matteo Civitali 1, MIlan, ITA, 20148
Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.

Recordati SpA (Recordati SpA) Headlines

From GuruFocus

Recordati: Isturisa® (Osilodrostat) Approved In The U.S.

By PRNewswire PRNewswire 03-09-2020